There are currently 38 active clinical trials seeking participants for Myelofibrosis research studies. The states with the highest number of trials for Myelofibrosis participants are California, Texas, New York and Ohio.
To Assess the Safety, Tolerability and Efficacy of Itacitinib Immediate Release Tablets in Participants With Primary or Secondary Myelofibrosis Who Have Received Prior Ruxolitinib and/or Fedratinib Monotherapy. (LIMBER-213)
NCT04821791
Recruiting
This is a 2-part study. In Part 1, participants will be dosed at 2 different dose levels in order to select the RP2D for Part 2 of the study.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/27/2021
Locations: New Jersey Hematology Oncology Associates Llc, Brick, New Jersey +1 locations
Conditions: Myelofibrosis, Polycythemia Vera, Thrombocythemia
Register for Updates
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
NCT04816578
Recruiting
The purpose of the study is to compare the efficacy of parsaclisib when combined with ruxolitinb versus placebo combined with ruxolitinib in participants with myelofibrosis.
Gender:
All
Ages:
18 years and above
Trial Updated:
03/24/2021
Locations: CCARE, Fresno, California +5 locations
Conditions: Myelofibrosis, Primary Myelofibrosis, Post Essential Thrombocythemia Myelofibrosis, Post Polycythemia Vera Myelofibrosis
Register for Updates